1. United States Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Biomolecular Life Holdings, Inc.

Biomolecular Life Holdings, Inc.

OOTC:BIOM
0.89
USD
-0.02
(-2.20%)
-0.07EPS
99.57BMarket Cap
2001 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2013 Y
2014 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-12.22
-25.61
-27.53
-61.7
-69.27
-29.67
-72.25
-0.91
-0.22
-0.07
Free Cash Flow per Basic Share
-9.56
-6.86
-4.23
-13.58
-11.81
-19.78
-22.91
-0.13
-0.07
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-188.47
-65.17
-62.51
-54.43
28.45
19.5
-38.7
-0.17
-0.11
-0.05
Tangible Book Value per Share
-188.47
-147.82
-139.2
-118.02
-6.21
-12.07
-38.7
-0.2
-0.14
-0.06
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
8
28
63
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-2
-4
-7
-5
-13
-7
-6
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
-7
-2
1
-1
- -
-6
-6
-5
LT Debt
8
9
3
8
2
2
2
- -
- -
- -
Total Equity
-3
-4
-4
-4
4
3
-7
-4
-5
-4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-122.55
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
ST Debt
4
4
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
77
102
Market Capitalization
86,033
100,343
99,572

Working Capital

USD

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
6
5
Payables & Accruals
1
1
1
ST Debt
4
4
3
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-117.7%
0.84%
Free Cash Flow
- -
43.97%
83.96%
Net Income, GAAP
- -
27.99%
-16.58%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
0.44
-4.73
-0.18
-0.1
-0.91
2014
-0.14
-0.09
-0.04
-0.01
-0.22
2015
-0.03
-0.02
-0.01
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
William P. Farrand
Sector
Health technology
Industry
Biotechnology
Address
New York United States
CIK
0001091326
Website
vglscorp.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Biomolecular Life Holdings, Inc. is a life sciences and biotechnology company focused on the development, manufacturing, and commercialization of advanced healthcare, longevity, and cellular wellness solutions. The company operates across integrated segments comprising nutraceuticals, personalized health diagnostics, and biopharmaceutical research. Its core product and service portfolio includes proprietary dietary supplements and therapeutic nutraceuticals designed to support metabolic function, immune defense, and cellular repair; specialized biomarker profiling panels and molecular diagnostic kits for preventative health assessment; clinical-grade longevity formulations and peptide-based nutritional products engineered to optimize mitochondrial performance; and comprehensive contract laboratory, formulation development, and analytical testing services for medical professionals and commercial partners. Biomolecular Life Holdings, Inc. distributes its offerings across direct-to-consumer digital channels, specialty wellness clinics, healthcare practitioner networks, and retail distributors throughout North America and expanding international markets. In recent operational developments, the company has executed several strategic initiatives, including establishing collaborative distribution and co-development partnerships with diagnostic laboratories; acquiring specialized wellness product lines and intellectual property assets to broaden its brand portfolio; introducing next-generation cellular rejuvenation formulas into its commercial lineup; expanding direct-to-consumer supply chain infrastructure; and implementing a corporate reorganization aimed at streamlining manufacturing efficiencies and accelerating market penetration in the longevity sector. Biomolecular Life Holdings, Inc. was founded in 2018 and is headquartered in the United States.